Medicenna Therapeutics Corp (MDNA)

NASDAQ
Currency in USD
Disclaimer
0.2990
+0.0040(+1.36%)
Closed
After Hours
0.2896-0.0094(-3.1438%)
Day's Range
0.27950.3090
52 wk Range
0.26850.9499
Prev. Close
0.295
Open
0.309
Day's Range
0.2795-0.309
52 wk Range
0.2685-0.9499
Volume
81,262
Average Vol. (3m)
227,302
1-Year Change
-65.98%
Shares Outstanding
69,637,469
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
5.1971
Upside +1,232.5897%
  • Medicenna Therapeutics Corp. Misses Q2 EPS by 1c
    • ByInvesting.com
  • Medicenna Therapeutics Appoints Jeff Caravella as CFO
    • ByInvesting.com
  • Medicenna Therapeutics Establishes Boston Presence
    • ByInvesting.com

Medicenna Therapeutics Corp Company Profile

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Income Statement